Herpes simplex virus oncolytic therapy for pediatric malignancies

Molecular Therapy

Volumn 17, Issue 7, 2009, Pages 1125-1135

  Friedman, Gregory K ^a   Pressey, Joseph G ^a   Reddy, Alyssa T ^b,c,d   Markert, James M ^d   Gillespie, G Yancey ^d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3616 UB; BEVACIZUMAB; CILENGITIDE; CYCLOPHOSPHAMIDE; G 207; GRANULOCYTE COLONY STIMULATING FACTOR; HSV 1716; ISOTRETINOIN; NECTIN 1; NV 1020; NV 1042; NV 1066; ONCOLYTIC HERPES VIRUS; ONCOVEX; R 3616; UNCLASSIFIED DRUG; VINCRISTINE;

ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ASTROCYTOMA; BRAIN TUMOR; BREAST CANCER; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; DRUG TOLERABILITY; EMBRYONAL RHABDOMYOSARCOMA; EPENDYMOMA; GERM CELL TUMOR; GLIOBLASTOMA; GROOMING; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; LUNG METASTASIS; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MELANOMA; MUCOSAL DISEASE; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PONS ANGLE TUMOR; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TERATOMA; WEIGHT REDUCTION;

BRAIN NEOPLASMS; HUMANS; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; SARCOMA; SIMPLEXVIRUS;

SIMPLEXVIRUS;

EID: 67649845838     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.73     Document Type: Review

References (146)

1. Gatta, G, Capocaccia, R, Coleman, MP, Ries, LA and Berrino, F (2002). Childhood cancer survival in Europe and the United States. Cancer 95: 1767-1772.
2. Ries, LAG, Melbert, D, Krapcho, M, Mariotto, A, Miller, BA, Feuer, EJ et al., (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD , based on November 2006 SEER data submission, posted to the SEER Web site, 2007.
3. Markert, JM, Parker, JN, Gillespie, GY and Whitley, RJ (2001). Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes 8: 17-22.
4. Shah, AC, Benos, D, Gillespie, GY and Markert, JM (2003). Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 65: 203-226.
5. Bharatan, NS, Currier, MA and Cripe, TP (2002). Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol 24: 447-453.
6. Kemeny, N, Brown, K, Covey, A, Kim, T, Bhargava, A, Brody, L et al. (2006). Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214-1224.
7. Liu, R, Martuza, RL and Rabkin, SD (2005). Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 12: 647-654.
8. Yu, Z, Chan, MK, O-charoenrat, P, Eisenberg, DP, Shah, JP, Singh, B et al. (2005). Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res 11: 4889-4897.
9. Varghese, S, Rabkin, SD, Nielsen, GP, MacGarvey, U, Liu, R and Martuza, RL (2007). Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 67: 9371-9379.
10. Watanabe, D, Goshima, F, Mori, I, Tamada, Y, Matsumoto, Y and Nishiyama, Y (2008). Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 50: 185-196.
11. Chou, J, Kern, ER, Whitley, RJ and Roizman, B (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250: 1262-1266.
12. Mineta, T, Rabkin, SD, Yazaki, T, Hunter, WD and Martuza, RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943.
13. MacLean, AR, ul-Fareed, M, Robertson, L, Harland, J and Brown, SM (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 72 (Pt 3): 631-639.
14. Chambers, R, Gillespie, GY, Soroceanu, L, Andreansky, S, Chatterjee, S, Chou, J et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 92: 1411-1415.
15. Bolovan, CA, Sawtell, NM and Thompson, RL (1994). ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 68: 48-55.
16. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867-874.
17. Markert, JM, Parker, JN, Buchsbaum, DJ, Grizzle, WE, Gillespie, GY and Whitley, RJ (2006). Oncolytic HSV-1 for the treatment of brain tumours. Herpes 13: 66-71.
18. Rampling, R, Cruickshank, G, Papanastassiou, V, Nicoll, J, Hadley, D, Brennan, D et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866.
19. Papanastassiou, V, Rampling, R, Fraser, M, Petty, R, Hadley, D, Nicoll, J et al. (2002). The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther 9: 398-406.
20. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 11: 1648-1658.
21. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747.
22. Herrlinger, U, Kramm, CM, Aboody-Guterman, KS, Silver, JS, Ikeda, K, Johnston, KM et al. (1998). Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5: 809-819.
23. Chahlavi, A, Rabkin, S, Todo, T, Sundaresan, P and Martuza, R (1999). Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6: 1751-1758.
24. Delman, KA, Bennett, JJ, Zager, JS, Burt, BM, McAuliffe, PF, Petrowsky, H et al. (2000). Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 11: 2465-2472.
25. Lambright, ES, Kang, EH, Force, S, Lanuti, M, Caparrelli, D, Kaiser, LR et al. (2000). Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2: 387-393.
26. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
27. Parker, JN, Gillespie, GY, Love, CE, Randall, S, Whitley, RJ and Markert, JM (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97: 2208-2213.
28. Fulci, G, Dmitrieva, N, Gianni, D, Fontana, EJ, Pan, X, Lu, Y et al. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 67: 9398-9406.
29. Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
30. Currier, MA, Gillespie, RA, Sawtell, NM, Mahller, YY, Stroup, G, Collins, MH et al. (2008). Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 16: 879-885.
31. Kurozumi, K, Hardcastle, J, Thakur, R, Shroll, J, Nowicki, M, Otsuki, A et al. (2008). Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16: 1382-1391.
32. Kaur, B, Brat, DJ, Devi, NS and Van Meir, EG (2005). Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24: 3632-3642.
33. Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci USA 103: 5508-5513.
34. Kamiyama, H, Zhou, G and Roizman, B (2006). Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther 13: 621-629.
35. Zhou, G and Roizman, B (2005). Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol 79: 5272-5277.
36. Mezhir, JJ, Advani, SJ, Smith, KD, Darga, TE, Poon, AP, Schmidt, H et al. (2005). Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res 65: 9479-9484.
37. Advani, SJ, Mezhir, JJ, Roizman, B and Weichselbaum, RR (2006). ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66: 637-646.
38. Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50.
39. Smith, KD, Mezhir, JJ, Bickenbach, K, Veerapong, J, Charron, J, Posner, MC et al. (2006). Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80 1110-1120.
40. Shah, AC, Parker, JN, Gillespie, GY, Lakeman, FD, Meleth, S, Markert, JM et al. (2007). Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther 14: 1045-1054.
41. Ganesh, S, Gonzalez-Edick, M, Gibbons, D, Van Roey, M and Jooss, K (2008). Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 14: 3933-3941.
42. Packer, RJ, Rood, BR and MacDonald, TJ (2003). Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg 39: 60-67.
43. Crawford, JR, MacDonald, TJ and Packer, RJ (2007). Medulloblastoma in childhood: New biological advances. Lancet Neurol 6: 1073-1085.
44. Chastagner, P, Kalifa, C, Doz, F, Bouffet, E, Gentet, JC, Ruchoux, MM et al. (2007). Outcome of children treated with preradiation chemotherapy for a high-grade glioma: Results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 49 803-807.
45. MacDonald, TJ, Arenson, EB, Ater, J, Sposto, R, Bevan, HE, Bruner, J et al. (2005). Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: Final analysis of Children's Cancer Group Study 9933. Cancer 104: 2862-2871.
46. Korones, DN, Fisher, PG, Kretschmar, C, Zhou, T, Chen, Z, Kepner, J et al. (2008). Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children's Oncology Group phase II study. Pediatr Blood Cancer 50: 227-230.
47. Dunkel, IJ, Garvin, JH Jr, Goldman, S, Ettinger, LJ, Kaplan, AM, Cairo, M et al. (1998). High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neurooncol 37: 67-73.
48. Hargrave, D, Bartels, U and Bouffet, E (2006). Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol 7 241-248.
49. Gidwani, P, Levy, A, Goodrich, J, Weidenheim, K and Kolb, EA (2008). Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol 88: 211-215.
50. Nazar, GB, Hoffman, HJ, Becker, LE, Jenkin, D, Humphreys, RP and Hendrick, EB (1990). Infratentorial ependymomas in childhood: Prognostic factors and treatment. J Neurosurg 72: 408-417.
51. Duffner, PK, Horowitz, ME, Krischer, JP, Friedman, HS, Burger, PC, Cohen, ME et al. (1993). Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328: 1725-1731.
52. Pierre-Kahn, A, Hirsch, JF, Roux, FX, Renier, D and Sainte-Rose, C (1983). Intracranial ependymomas in childhood. Survival and functional results of 47 cases. Childs Brain 10: 145-156.
53. Shu, HK, Sall, WF, Maity, A, Tochner, ZA, Janss, AJ, Belasco, JB et al. (2007). Childhood intracranial ependymoma: Twenty-year experience from a single institution. Cancer 110: 432-441.
54. Sundaresan, P, Hunter, WD, Martuza, RL and Rabkin, SD (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol 74: 3832-3841.
55. Hunter, WD, Martuza, RL, Feigenbaum, F, Todo, T, Mineta, T, Yazaki, T et al. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol 73: 6319-6326.
56. Lopez, C (1981). Resistance to herpes simplex virus - type 1 (HSV-1). Curr Top Microbiol Immunol 92: 15-24.
57. Lopez, C (1980). Resistance to HSV-1 in the mouse is governed by two major, independently segregating, non-H-2 loci. Immunogenetics 11: 87-92.
58. Radbill, AE, Reddy, AT, Markert, JM, Wyss, JM, Pike, MM, Akella, NS et al. (2007). Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol 13: 118-129.
59. Neuwelt, EA, Pagel, MA and Dix, RD (1991). Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 74: 475-479.
60. Pardridge, WM (2002). Drug and gene delivery to the brain: The vascular route. Neuron 36: 555-558.
61. Neuwelt, EA, Pagel, MA and Dix, RD (1991). Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 74: 475-479.
62. Rainov, NG, Zimmer, C, Chase, M, Kramm, CM, Chiocca, EA, Weissleder, R et al. (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 6: 1543-1552.
63. Cloughesy, TF and Black, KL (1995). Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26: 125-132.
64. Nilaver, G, Muldoon, LL, Kroll, RA, Pagel, MA, Breakefield, XO, Davidson, BL et al. (1995). Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 92: 9829-9833.
65. Mohr, I and Gluzman, Y (1996). A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 15: 4759-4766.
66. Friedman, GK, Bharara, S, Langford, C, Coleman, J and Gillespie, GY (2008). Engineered herpes simpex virus oncolytic therapy kills both tumor cells and glioma progenitor cells in a pediatric high-grade glioma. Poster presentation at the International Symposium of Pediatric Neuro-Oncology Meeting, June 2008.
67. Friedman, GK, Bharara, S, Langford, C, Coleman, J and Gillespie, GY (2007). Heterogeneity of CD111 (nectin-1) expression governs infection of human glioma tumor or progenitor cells by genetically engineered herpes simplex virus. Poster presentation at the Society of Neuro-Oncology Scientific Meeting, November 2007.
68. Otsuki, A, Patel, A, Kasai, K, Suzuki, M, Kurozumi, K, Chiocca, EA et al. (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555.
69. Chinnaiyan, P, Wang, M, Rojiani, AM, Tofilon, PJ, Chakravarti, A, Ang, KK et al. (2008). The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. Radiat Oncol 3: 32.
70. Fomchenko, EI and Holland, EC (2007). Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am 18: 39-58.
71. Assanah, M, Lochhead, R, Ogden, A, Bruce, J, Goldman, J and Canoll, P (2006). Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 26: 6781-6790.
72. Lasner, TM, Kesari, S, Brown, SM, Lee, VM, Fraser, NW and Trojanowski, JQ (1996). Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 55: 1259-1269.
73. Pyles, RB, Warnick, RE, Chalk, CL, Szanti, BE and Parysek, LM (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 8: 533-544.
74. Guzman, G, Oh, S, Shukla, D, Engelhard, HH and Valyi-Nagy, T (2006). Expression of entry receptor nectin-1 of herpes simplex virus 1 and/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta Virol 50: 59-66.
75. Huang, YY, Yu, Z, Lin, SF, Li, S, Fong, Y and Wong, RJ (2007). Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 92: 1965-1970.
76. Yu, Z, Adusumilli, PS, Eisenberg, DP, Darr, E, Ghossein, RA, Li, S et al. (2007). Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 15: 103-113.
77. Gurney, JG, Davis, S, Severson, RK, Fang, JY, Ross, JA and Robison, LL (1996). Trends in cancer incidence among children in the U.S. Cancer 78: 532-541.
78. Friedman, GK and Castleberry, RP (2007). Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 49(7 Suppl): 1060-1065.
79. Matthay, KK, Villablanca, JG, Seeger, RC, Stram, DO, Harris, RE, Ramsay, NK et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
80. Santana, VM, Furman, WL, McGregor, LM and Billups, CA (2008). Disease control intervals in high-risk neuroblastoma. Cancer 112: 2796-2801.
81. Wong, RJ, Chan, MK, Yu, Z, Kim, TH, Bhargava, A, Stiles, BM et al. (2004). Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10(1 Pt 1): 251-259.
82. Varghese, S, Rabkin, SD, Nielsen, PG, Wang, W and Martuza, RL (2006). Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 12: 2919-2927.
83. Veerapong, J, Bickenbach, KA, Shao, MY, Smith, KD, Posner, MC, Roizman, B et al. (2007). Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 67: 8301-8306.
84. Roizman, B, Whitley, R and Lopez, C (1993). The Human Herpesviruses: Biology, Pathogenesis, and Treatment. Raven: New York.
85. Xu, F, Lee, FK, Morrow, RA, Sternberg, MR, Luther, KE, Dubin, G et al. (2007). Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr 151: 374-377.
86. Xu, F, Sternberg, MR, Kottiri, BJ, McQuillan, GM, Lee, FK, Nahmias, AJ et al. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296: 964-973.
87. Hock, RA, Reynolds, BD, Tucker-McClung, CL and Heuer, JG (1996). Murine neuroblastoma vaccines produced by retroviral transfer of MHC class II genes. Cancer Gene Ther 3: 314-320.
88. Rasty, S, Poliani, PL, Fink, DJ and Glorioso, JC (1997). Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central nervous system. J Neurovirol 3: 247-264.
89. Todo, T, Rabkin, SD, Sundaresan, P, Wu, A, Meehan, KR, Herscowitz, HB et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755.
90. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401.
91. Todo, T, Martuza, RL, Dallman, MJ and Rabkin, SD (2001). In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 61: 153-161.
92. Orentas, RJ, Schauer, D, Bin, Q and Johnson, BD (2001). Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 213: 4-13.
93. Schwab, M, Ellison, J, Busch, M, Rosenau, W, Varmus, HE and Bishop, JM (1984). Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 81: 4940-4944.
94. Brodeur, GM, Seeger, RC, Schwab, M, Varmus, HE and Bishop, JM (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
95. Seeger, RC, Brodeur, GM, Sather, H, Dalton, A, Siegel, SE, Wong, KY et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
96. Guffey, MB, Parker, JN, Luckett, WS Jr, Gillespie, GY, Meleth, S, Whitley, RJ et al. (2007). Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther 14: 45-56.
97. Li, H, Dutuor, A, Tao, L, Fu, X and Zhang, X (2007). Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13 316-322.
98. Ino, Y, Saeki, Y, Fukuhara, H and Todo, T (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12: 643-652.
99. Fukuhara, H, Ino, Y, Kuroda, T, Martuza, RL and Todo, T (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65: 10663-10668.
100. Parikh, NS, Currier, MA, Mahller, YY, Adams, LC, Di Pasquale, B, Collins, MH et al. (2005). Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 44: 469-478.
101. Keshelava, N, Seeger, RC, Groshen, S and Reynolds, CP (1998). Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405.
102. Negroni, A, Scarpa, S, Romeo, A, Ferrari, S, Modesti, A and Raschellà, G (1991). Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 2: 511-518.
103. Mahller, YY, Vaikunth, SS, Ripberger, MC, Baird, WH, Saeki, Y, Cancelas, JA et al. (2008). Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 68: 1170-1179.
104. Ribatti, D, Surico, G, Vacca, A, De Leonardis, F, Lastilla, G, Montaldo, PG et al. (2001). Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 68: 1161-1168.
105. Sakakibara, M, Koizumi, S, Saikawa, Y, Wada, H, Ichihara, T, Sato, H et al. (1999). Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 85: 231-239.
106. Ara, T, Fukuzawa, M, Kusafuka, T, Komoto, Y, Oue, T, Inoue, M et al. (1998). Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: Association with tumor progression and clinical outcome. J Pediatr Surg 33: 1272-1278.
107. Mahller, YY, Williams, JP, Baird, WH, Mitton, B, Grossheim, J, Saeki, Y et al. (2009). Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4: E4235.
108. Paulino, AC and Okcu, MF (2008). Rhabdomyosarcoma. Curr Probl Cancer 32: 7-34.
109. Xia, SJ, Pressey, JG and Barr, FG (2002). Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1: 97-104.
110. Visser, M, Sijmons, C, Bras, J, Arceci, RJ, Godfried, M, Valentijn, LJ et al. (1997). Allelotype of pediatric rhabdomyosarcoma. Oncogene 15: 1309-1314.
111. Breneman, JC, Lyden, E, Pappo, AS, Link, MP, Anderson, JR, Parham, DM et al. (2003). Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78-84.
112. Crist, W, Gehan, EA, Ragab, AH, Dickman, PS, Donaldson, SS, Fryer, C et al. (1995). The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-630.
113. Maurer, HM, Gehan, EA, Beltangady, M, Crist, W, Dickman, PS, Donaldson, SS et al. (1993). The Intergroup Rhabdomyosarcoma Study-II. Cancer 71: 1904-1922.
114. Linet, MS, Ries, LA, Smith, MA, Tarone, RE and Devesa, SS (1999). Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91: 1051-1058.
115. Spunt, SL, Hill, DA, Motosue, AM, Billups, CA, Cain, AM, Rao, BN et al. (2002). Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol 20: 3225-3235.
116. Spunt, SL, Poquette, CA, Hurt, YS, Cain, AM, Rao, BN, Merchant, TE et al. (1999). Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: An analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 17: 3697-3705.
117. Pratt, CB, Maurer, HM, Gieser, P, Salzberg, A, Rao, BN, Parham, D et al. (1998). Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group study. Med Pediatr Oncol 30: 201-209.
118. Hansen, MF, Koufos, A, Gallie, BL, Phillips, RA, Fodstad, O, Brogger, A et al. (1985). Osteosarcoma and retinoblastoma: A shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82: 6216-6220.
119. Miller, CW, Aslo, A, Tsay, C, Slamon, D, Ishizaki, K, Toguchida, J et al. (1990). Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50: 7950-7954.
120. Delattre, O, Zucman, J, Melot, T, Garau, XS, Zucker, JM, Lenoir, GM et al. (1994). The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294-299.
121. Miser, JS, Krailo, MD, Tarbell, NJ, Link, MP, Fryer, CJ, Pritchard, DJ et al. (2004). Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22: 2873-2876.
122. Meyers, PA, Heller, G, Healey, JH, Huvos, A, Applewhite, A, Sun, M et al. (1993). Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11: 449-453.
123. Miser, JS, Goldsby, RE, Chen, Z, Krailo, MD, Tarbell, NJ, Link, MP et al. (2007). Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy - a report from the Children's Oncology Group. Pediatr Blood Cancer 49: 894-900.
124. Bruland, OS and Pihl, A (1997). On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33: 1725-1731.
125. Currier, MA, Adams, LC, Mahller, YY and Cripe, TP (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 12: 407-416.
126. Cinatl, J Jr, Cinatl, J, Michaelis, M, Kabickova, H, Kotchetkov, R, Vogel, JU et al. (2003). Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 63: 1508-1514.
127. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
128. Lan, P, Dong, C, Qi, Y, Xiao, G and Xue, F (2003). Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene, icp34.5. J Biochem Mol Biol 36: 379-386.
129. Sugiura, S, Goshima, F, Takakuwa, H, Sata, T, Nakashima, T and Nishiyama, Y (2004). Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses. Otolaryngol Head Neck Surg 130: 470-478.
130. Yamamura, H, Hashio, M, Noguchi, M, Sugenoya, Y, Osakada, M, Hirano, N et al. (2001). Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 61: 3969-3977.
131. Takahashi, K and Nadal-Ginard, B (1991). Molecular cloning and sequence analysis of smooth muscle calponin. J Biol Chem 266: 13284-13288.
132. Jenson, HB, Montalvo, EA, McClain, KL, Ench, Y, Heard, P, Christy, BA et al. (1999). Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma. J Med Virol 57: 36-46.
133. Miettinen, MM, Sarlomo-Rikala, M, Kovatich, AJ and Lasota, J (1999). Calponin and h-caldesmon in soft tissue tumors: Consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation. Mod Pathol 12: 756-762.
134. Ono, H, Yoshikawa, H, Ueda, T, Yamamura, H, Kudawara, I, Manou, M et al. (1997). Expression of smooth muscle calponin in synovial sarcoma. Sarcoma 2: 107-113.
135. Horiuchi, A, Nikaido, T, Ya-Li, Z, Ito, K, Orii, A and Fujii, S (1999). Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Mol Hum Reprod 5: 139-145.
136. Yamamura, H, Yoshikawa, H, Tatsuta, M, Akedo, H and Takahashi, K (1998). Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer 79: 245-250.
137. Goldstein, DJ and Weller, SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196-205.
138. Meignier, B, Longnecker, R and Roizman, B (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158: 602-614.
139. Meignier, B, Martin, B, Whitley, RJ and Roizman, B (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162: 313-321.
140. Packer, RJ (2005). Progress and challenges in childhood brain tumors. J Neurooncol 75: 239-242.
141. McNeil, DE, Coté, TR, Clegg, L and Rorke, LB (2002). Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 39: 190-194.
142. Echevarría, ME, Fangusaro, J and Goldman, S (2008). Pediatric central nervous system germ cell tumors: A review. Oncologist 13: 690-699.
143. Punyko, JA, Mertens, AC, Baker, KS, Ness, KK, Robison, LL and Gurney, JG (2005). Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 103: 1475-1483.
144. Ferrari, A, Casanova, M, Collini, P, Meazza, C, Luksch, R, Massimino, M et al. (2005). Adult-type soft tissue sarcomas in pediatric-age patients: Experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 23: 4021-4030.
145. Foster, L, Dall, GF, Reid, R, Wallace, WH and Porter, DE (2007). Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br 89: 1234-1238.
146. Esiashvili, N, Goodman, M and Marcus, RB Jr (2008). Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430.